Press release
Dopamine Agonists Market to Reach USD 1.73 Billion by 2033, Growing at 5.4% CAGR | Driven by Parkinson's & RLS Treatment Demand
Dopamine Agonists Market
The Dopamine Agonists Market is shaped by major pharmaceutical players including Teva Pharmaceuticals, GSK, Supernus Pharmaceuticals, Lundbeck, Amneal, UCB Pharma, Novartis, Pfizer, Boeringer Ingelheim, and others. These companies lead in the R&D of both ergot and non-ergot agonists, focusing on enhanced drug delivery, safety profiles, and long-acting formulations, primarily catering to patients with Parkinson's disease and restless legs syndrome (RLS) as per our analysis.
Download your exclusive sample report today: https://www.datamintelligence.com/download-sample/dopamine-agonists-market?jd
Dopamine Agonists Market M&A & Strategic Collaborations
• In August 2024, AbbVie acquired Cerevel Therapeutics (USD 8.7B) to strengthen its neurology portfolio and access novel dopamine-related assets.
• Recent partnerships highlight focus on extended-release oral and injectable therapies tailored for advanced Parkinson's patients, especially in emerging markets.
Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/dopamine-agonists-market?jd
Key Growth Drivers & Emerging Opportunities in the Dopamine Agonists Market
• Rising prevalence of neurodegenerative disorders, Parkinson's affects over 10M people globally; one million in the U.S., projected to 1.2M by 2030.
• Preferential uptake of non-ergot agents (e.g., pramipexole, ropinirole) due to improved safety and efficacy.
• Innovation in oral long-acting and transdermal delivery systems, enhancing compliance and reducing motor fluctuations.
• Personalized neurology approaches, including genomic profiling and tailored dosing strategies.
• Rapid growth in RLS treatment adoption, driven by aging demographics, awareness campaigns, and guideline updates positioning dopamine agonists as first-line therapy.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=dopamine-agonists-market?jd
Regional Market Drivers in the Dopamine Agonists Market
North America: Expected to lead globally with ~38-39% share by 2030 (~USD 701.9M), supported by healthcare infrastructure, drug adoption, and retail pharmacy access.
Europe: Steady growth driven by aging populations, reimbursement access, and research investments.
Asia-Pacific: Fastest CAGR (~6-7%) with the region projected to grow from USD 300.4M in 2024 to USD 428.8M by 2030; Japan leads growth.
Latin America & MEA: Emerging opportunities fuelled by rising healthcare access and increasing awareness of neurological disorders.
Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?jd
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis for Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?jd
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights, and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains, creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dopamine Agonists Market to Reach USD 1.73 Billion by 2033, Growing at 5.4% CAGR | Driven by Parkinson's & RLS Treatment Demand here
News-ID: 4113931 • Views: …
More Releases from DataM Intelligence 4Market Research LLP
Food Safety Testing Market to Reach US$40.1 Billion by 2029 at 9.0% CAGR, Led by …
The Food Safety Testing Market reached approximately US$ 24.5 billion in 2024 and is expected to grow to around US$ 40.1billion by 2029, expanding at a CAGR of about 9.0% from 2025 to 2029 as food industry stakeholders and regulatory bodies intensify efforts to ensure product safety, quality, and compliance across global supply chains.
Growth is supported by increasing demand across key segments such as microbiological testing, chemical residue analysis, allergen…
Food Ingredients Market to Reach US$538.68 Billion by 2032 at 5.45% CAGR, Driven …
The Food Ingredients Market Size reached US$ 352.34 billion in 2024 and is expected to reach US$ 538.68 billion by 2032, growing with a CAGR of 5.45% from 2025 to 2032. as food and beverage manufacturers intensify investments in value‐added and functional ingredients to meet evolving consumer preferences and regulatory standards.
Growth is supported by increasing demand across key categories such as flavors & fragrances, sweeteners, proteins & amino acids, emulsifiers,…
Aluminum Extrusion Market to Reach US$ 117.8 Billion by 2030 Driven by Infrastru …
The Aluminum Extrusion Market reached US$ 78.7 billion in 2022 and is expected to reach US$ 117.8 billion by 2030, growing at a CAGR of 5.7% during the forecast period 2025-2031.
Growth is driven by increasing demand from the construction, automotive, aerospace, and industrial sectors, where aluminum extrusions are widely used for their lightweight properties, strength, corrosion resistance, and design flexibility. Rising focus on fuel efficiency and vehicle lightweighting, along with…
Smart Farming Market to Reach US$22.45 Billion by 2031 at 9.1% CAGR, Led by Nort …
The Smart Farming Market reached US$ 11.12 billion in 2022 and is expected to reach US$ 22.45 billion by 2031, growing with a CAGR of 9.1% from 2024 to 2031. as agricultural stakeholders increasingly deploy IoT‐enabled technologies and data‐driven solutions to optimize farm productivity, resource efficiency, and sustainability.
Growth is supported by rising demand across key solutions such as precision agriculture tools, smart sensors, GPS‐enabled machinery, autonomous equipment, and farm management…
More Releases for Dopamine
Dopamine Agonist Market Current Scenario with Future Aspect Analysis
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " Dopamine Agonist Market - (By Drug (Ergot Alkaloids, Non-Ergot Dopamine Agonists), By Application (Parkinson's Disease, Restless Legs Syndrome (RLS), Hyperprolactinemia, Others), By Route of Administration (Oral, Injectable, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."
According to the latest research by InsightAce Analytic, the Dopamine…
Dopamine Hydrochloride API Market 2025: Sustainable Growth, Key Trends, and Indu …
LOS ANGELES, United States: QY Research has recently published a research report titled, "Dopamine Hydrochloride API - Market Insights, Industry Share, Sales Projections, and Demand Outlook 2024-2030" assessing various factors impacting its trajectory. The global Dopamine Hydrochloride API market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of…
Dopamine Manufacturing Plant Project Report 2024, Business Plan, Cost and Revenu …
IMARC Group's report titled "Dopamine Manufacturing Plant Project Report 2024: Industry Trends, Plant Setup, Machinery, Raw Materials, Investment Opportunities, Cost and Revenue" provides a comprehensive guide for establishing a dopamine manufacturing plant. The report covers various aspects, ranging from a broad market overview to intricate details like unit operations, raw material and utility requirements, infrastructure necessities, machinery requirements, manpower needs, packaging and transportation requirements, and more.
In addition to the operational…
Dopamine Antagonist Market Size, Growth Analysis and Forecast To 2029
The Dopamine Antagonist market research report is proficient and top to bottom research by specialists on the current state of the industry. This statistical surveying report gives the most up to date industry information and industry future patterns, enabling you to distinguish the items and end clients driving income development and benefit. It centres around the real drivers and restrictions for the key players and present challenge status with development…
Serotonin-Dopamine Activity Modulators Market Insights, Forecast to 2031
The report extensively examines the global Serotonin-Dopamine Activity Modulators market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Serotonin-Dopamine Activity Modulators . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers influencing the…
Serotonin-Dopamine Activity Modulators Market Report, History and Forecast 2023- …
Newark, New Castle, USA - Growth Plus Reports has published a comprehensive research report of the Serotonin-Dopamine Activity Modulators Market, which include a detailed study of the product offerings, advancements, applications, benefits, and scope. The report covers significant strategic developments in addition to R&D, launches of new products, acquisitions and mergers, partnerships, alliances, agreements, limited partnerships, and the regional growth of fundamental competitors operating at the global and local…
